What is the current stock price of InspireMD, Inc. (NSPR)?

As of the latest market data, InspireMD, Inc. (NSPR) is trading at $1.29. The stock has seen a loss of -3.73% today.

Does InspireMD, Inc. (NSPR) pay a dividend?

Based on current data, InspireMD, Inc. does not have a confirmed active dividend policy.

What is the market cap of InspireMD, Inc.?

The current market capitalization of InspireMD, Inc. (NSPR) is approximately unavailable.

NSPR

InspireMD, Inc.·Healthcare

1.29

3.731%(−0.05)

Market Closed

1.45

12.403%(+0.16)

After Hours

Last Updated: — ET

52W L: $1.2852W H: $2.93

NSPR NEWS

zacks.com

2d ago

After Plunging 15.2% in 4 Weeks, Here's Why the Trend Might Reverse for InspireMD (NSPR)

InspireMD (NSPR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

defenseworld.net

3d ago

InspireMD (NYSE:NSPR) Trading Down 6.7% – What’s Next?

InspireMD, Inc. (NYSE: NSPR - Get Free Report) was down 6.7% on Tuesday. The stock traded as low as $1.38 and last traded at $1.39. Approximately 15,207 shares were traded during trading, a decline of 56% from the average daily volume of 34,694 shares. The stock had previously closed at $1.49. Analyst Upgrades and Downgrades

globenewswire.com

Mar 31

InspireMD to Participate in Upcoming 25th Annual Needham Virtual Healthcare Conference

MIAMI, March 31, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to present at the upcoming 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14th at 12:45 pm Eastern Time (ET).

seekingalpha.com

Mar 18

InspireMD, Inc. (NSPR) Q4 2025 Earnings Call Transcript

zacks.com

Mar 18

InspireMD, Inc. (NSPR) Reports Q4 Loss, Beats Revenue Estimates

InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.19 per share a year ago.

globenewswire.com

Mar 18

InspireMD Reports Fourth Quarter and Full Year 2025 Financial Results

MIAMI, March 18, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the fourth quarter and year ended December 31, 2025. Recent Business Highlights: Generated revenue of $3.1 million in the fourth quarter of 2025, up 62% year-over-year.

Company Profile

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

Sector

Healthcare

Industry

Medical - Devices

Employees

IPO Date

2011-04-12

Beta

0.94

Websitewww.inspiremd.com↗